The Children's Hospital, Sheffield, S10 2th, England. HE HIGH FREQUENCY and the seriousness of complications resulting from any form of shunt treatment makes this otherwise excellent method of treatment of hydrocephalus an extremely hazardous procedure. &dquo;Revisions&dquo; may have to be carried out on numerous occasions, since blockages and infections of the shunt system can threaten life, vision, and intelligence. Early shunting is particularly dangerous.' In a very large series of patients whose hydrocephalus was part of the spina bifida complex, the mortality rate of 20 per cent within seven years of the first operation was directly attributable to shunt complications.2 These widely known facts make it necessary to look for alternative and safer methods to treat hydrocephalus which would not necessarily be as final and practically irreversible as the present surgical techniques.
One promising drug which has emerged as a possible alternative to surgical treatment is isosorbide. This crystalline substance, 1,4 :3,6dianhydro-D-glucitol, is a derivative of mannitol.
An osmotic agent, isosorbide is capable of reducing the formation of cerebrospinal fluid (CSF) without inducing a significant diuresis. Since January, 197 1, I have used isosorbide in the treatment of 90 infants with all types of infantile hydrocephalus.
First Trial
This clinical study has had two phases. In the first phase up to August, 1972, 60 infants were treated, irrespective of the type and degree of their hydrocephalus. Included in this study was a controlled therapeutic trial in the management of hydrocephalus associated with spina bifida, carried out with 26 infants starting at one week of age. In the first phase, the duration of treatment, subject to satisfactory response, was limited to four weeks. The standard starting dose was 2 g/kg body weight at six hourly intervals. The dose was raised by up to 50 per cent when the response was insufficient and when no serious clinical or biochemical side effects occurred.
In infants with a satisfactory response, the dose was gradually tapered off after three weeks and treatment was concluded after a total of 4 weeks.2,4
This study showed that grossly hydrocephalic infants with a cerebral mantle of 15 mm or less rarely responded adequately and surgery had to be carried out often before the planned course was completed. It also 917 FIG. 1. Head circumference chart showing effect of isosorbide, followed by rebound on reduced dosage and shunt therapy. showed that doses above the standard 2 g/kg four times daily were usually too toxic except during a brief period.
In contrast, isosorbide was frequently highly effective in infants whose cerebral mantle was over 15 mm and especially over 20 mm. Their intracranial tension returned to normal and their head circumference increased at a normal rate. That this was due to the isosorbide was shown by the controlled 918~~G . 2. Pneumoventriculograms at the beginning and the end of isosorbide therapy. No decrease in ventricular size.
trial and by the frequency of rebound after treatment was concluded. When a rebound was noted in the first trial, a ventriculocardiac shunting was done. Isosorbide was often useful in reducing the abnormal rate of head growth in infants with postmeningitic and posthemorrhagic hydrocephalus. With its help, one could often delay operation until an infant and his cerebrospinal fluid were fit for surgical interference. Two of five infants with posthemorrhagic hydrocephalus recovered without surgery.
Finally, isosorbide proved a useful cover in instances when the shunt had to be removed because of colonization. With it, major intracranial hypertension could be avoided until the patients were ready again to receive a new shunt. Occasionally, they managed to do without revision of the shunt.
With isosorbide there were no permanent sequelae or other side effects from hypernatremia, and there were no deaths. Nevertheless, it is essential to control the weight, the serum electrolytes and the acid base balance of the patients under treatment, except when they are receiving a small maintenance dose. Ten of 60 children treated with isosorbide in the first trial are alive and well two to three years later and have required no shunt.* Several others, who initially responded well to isosorbide, might have avoided surgical treatment had the isosorbide therapy continued longer. The first protocol did not allow for this.
Second Trial
The second study was planned after experiences in the first indicated the new directions to be followed. In the second study, the dura-.tion of treatment and number of courses were not limited, so long as a good response was maintained. Further, only those patients were treated who had either a good expectation that surgery would be avoidable, or where a ' delay prior to surgery was essential or de-* All the other survivors had shunt therapy. sirable, or with whom a delay would be beneficial, though not essential, so long as it did not involve additional hazard to the infant.
In this second trial, between September, 1972, and August, 1974, 34 patients were treated, including four who already had had a course in the first trial.
Fifteen had less severe degrees of hydrocephalus with a cerebral mantle of 15 mm or more. These were expected to respond so well that surgery would not be necessary.
One, a battered infant with posthemorrhagic hydrocephalus, did not respond and a shunt was inserted quickly to assure a return of his sight. This was achieved. The other 14 responded ; but in three, the response was not of sufficient degree to prevent operation, although a delay of over a month was achieved. Eleven infants responded fully and required no surgery. Among these, two patients with congenital hydrocephalus were treated for 11 months, the longest courses given so far. All infants with spina bifida and hydrocephalus with a cerebral mantle of 20 mm or more improved and required no shunt.
These observations suggest that, in the future, few babies born with spina bifida will need shunt therapy if they are carefully selected for treatment in the first place,1.3 and if isosorbide therapy is given within a few days of birth, as soon as progressive hydrocephalus has been demonstrated. Nineteen infants, including six with postmeningitic hydrocephalus, had more severe degrees of hydrocephalus or infected (CSF). With these, at best, only a worthwhile delay before shunt therapy could be expected from isosorbide administration. Delay is considered to have been worthwhile when an operation could safely be delayed by at least 28 days or until the infant's condition and CSF permitted operation following meningitis or intracranial hemorrhage. (Fig. 1 ). This objective was attained in nine infants, including a premature infant who at birth only weighed 1,500 g. (Fig. 2 ). In addition, in an older child, it was not necessary to reinsert the shunt after it was removed because it was colonized.
We experienced nine failures among the infants in this series treated with isosorbide; but all this meant was that the infants were operated on just a few days later. Very few side effects occurred in the second series, these consisted mainly of a single high serum sodium reading. This finding led to interruption of therapy with immediate return to normal; isosorbide was then resumed, when indicated, at a lower dose. ' 
Comments
These two trials indicate that isosorbide can be a useful adjunct in the management of hydrocephalus in infancy. When given early enough in moderate cases, it will often eliminate the need for surgery, especially in infants having spina bifida. In many other cases, a worthwhile delay can be achieved before operation becomes either possible or necessary.
Isosorbide has the advantage over surgery in being safer; furthermore, in case of failure it can always be followed by surgery, whereas the reverse is not the case. It is also much cheaper.
Nevertheless, isosorbide will not replace surgery for the majority of cases of hydrocephalus unassociated with spina bifida. Its effect is never so rapid as that of a shunt operation. The two methods of treatment each have their own indications. Unfortunately, isosorbide has not yet been released for general use.
